Leerink Partners Reiterates a Buy Rating on GoodRx Holdings (GDRX) With a $6 PT

GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best long-term penny stocks to buy right now. On August 19, Leerink Partners analyst Michael Cherny reiterated the Buy rating on GoodRx Holdings, Inc. (NASDAQ:GDRX), keeping the associated price target at $6.00.

The analyst based the rating on the company’s strategic advancements, stating he considers the recent agreement with Novo Nordisk to offer discounted prices for Wegovy and Ozempic to be a significant achievement for GoodRx Holdings, Inc.’s (NASDAQ:GDRX) manufacturer solutions segment.

The collaboration points towards the potential of GoodRx Holdings, Inc.’s (NASDAQ:GDRX) platform, connecting more than 70,000 retail pharmacies in the US with 5.5 million monthly active users and serving as a notable channel for direct-to-consumer pharmaceutical advertising.

GoodRx Holdings, Inc. (NASDAQ:GDRX) offers a consumer-focused digital healthcare platform that provides free consumer access to convenient medical provider consultations through telehealth, reduced prices for brand and generic medications, and extensive healthcare research and information.

While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.